vs
EXACT SCIENCES CORP（EXAS）与ROYAL GOLD INC（RGLD）财务数据对比。点击上方公司名可切换其他公司
EXACT SCIENCES CORP的季度营收约是ROYAL GOLD INC的1.9倍（$878.4M vs $469.1M），ROYAL GOLD INC净利率更高（60.0% vs -9.8%，领先69.8%），ROYAL GOLD INC同比增速更快（142.6% vs 23.1%），ROYAL GOLD INC自由现金流更多（$278.9M vs $120.4M），过去两年ROYAL GOLD INC的营收复合增速更高（64.2% vs 17.4%）
Exact Sciences是总部位于美国威斯康星州麦迪逊的分子诊断企业，专注于早期癌症检测领域。公司核心产品覆盖结直肠癌筛查与预防场景，其中Cologuard是全球首个获批的结直肠癌粪便DNA检测产品，同时还提供其他多种癌症的筛查服务及精准肿瘤检测解决方案。
Royal Gold Inc.是全球领先的贵金属流权与特许权经营企业，收购并管理多元化的矿业项目流权、净熔炼收益特许权及相关权益，资产覆盖黄金、白银、铜等品类，业务遍及多地区，无需直接承担采矿运营风险。
EXAS vs RGLD — 直观对比
营收规模更大
EXAS
是对方的1.9倍
$469.1M
营收增速更快
RGLD
高出119.4%
23.1%
净利率更高
RGLD
高出69.8%
-9.8%
自由现金流更多
RGLD
多$158.4M
$120.4M
两年增速更快
RGLD
近两年复合增速
17.4%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $878.4M | $469.1M |
| 净利润 | $-86.0M | $281.7M |
| 毛利率 | 70.1% | — |
| 营业利润率 | -9.4% | 63.3% |
| 净利率 | -9.8% | 60.0% |
| 营收同比 | 23.1% | 142.6% |
| 净利润同比 | 90.1% | 147.7% |
| 每股收益（稀释后） | $-0.45 | $3.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EXASRGLD
| Q1 26 | — | $469.1M | ||
| Q4 25 | $878.4M | $375.3M | ||
| Q3 25 | $850.7M | $252.1M | ||
| Q2 25 | $811.1M | $209.6M | ||
| Q1 25 | $706.8M | $193.4M | ||
| Q4 24 | $713.4M | $202.6M | ||
| Q3 24 | $708.7M | $193.8M | ||
| Q2 24 | $699.3M | $174.1M |
净利润EXASRGLD
| Q1 26 | — | $281.7M | ||
| Q4 25 | $-86.0M | $93.6M | ||
| Q3 25 | $-19.6M | $126.8M | ||
| Q2 25 | $-1.2M | $132.3M | ||
| Q1 25 | $-101.2M | $113.5M | ||
| Q4 24 | $-864.6M | $107.4M | ||
| Q3 24 | $-38.2M | $96.2M | ||
| Q2 24 | $-15.8M | $81.2M |
毛利率EXASRGLD
| Q1 26 | — | — | ||
| Q4 25 | 70.1% | 64.6% | ||
| Q3 25 | 68.6% | 73.6% | ||
| Q2 25 | 69.3% | 72.6% | ||
| Q1 25 | 70.8% | 69.4% | ||
| Q4 24 | 69.0% | 70.3% | ||
| Q3 24 | 69.4% | 66.6% | ||
| Q2 24 | 69.8% | 64.7% |
营业利润率EXASRGLD
| Q1 26 | — | 63.3% | ||
| Q4 25 | -9.4% | 56.2% | ||
| Q3 25 | -3.0% | 64.4% | ||
| Q2 25 | -0.3% | 67.7% | ||
| Q1 25 | -13.6% | 63.6% | ||
| Q4 24 | -122.8% | 65.9% | ||
| Q3 24 | -5.6% | 61.3% | ||
| Q2 24 | -3.8% | 58.6% |
净利率EXASRGLD
| Q1 26 | — | 60.0% | ||
| Q4 25 | -9.8% | 24.9% | ||
| Q3 25 | -2.3% | 50.3% | ||
| Q2 25 | -0.1% | 63.1% | ||
| Q1 25 | -14.3% | 58.7% | ||
| Q4 24 | -121.2% | 53.0% | ||
| Q3 24 | -5.4% | 49.7% | ||
| Q2 24 | -2.3% | 46.6% |
每股收益（稀释后）EXASRGLD
| Q1 26 | — | $3.30 | ||
| Q4 25 | $-0.45 | $1.04 | ||
| Q3 25 | $-0.10 | $1.92 | ||
| Q2 25 | $-0.01 | $2.01 | ||
| Q1 25 | $-0.54 | $1.72 | ||
| Q4 24 | $-4.69 | $1.63 | ||
| Q3 24 | $-0.21 | $1.46 | ||
| Q2 24 | $-0.09 | $1.23 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $964.7M | $234.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $2.4B | $7.5B |
| 总资产 | $5.9B | $9.5B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资EXASRGLD
| Q1 26 | — | $234.1M | ||
| Q4 25 | $964.7M | $233.7M | ||
| Q3 25 | $1.0B | $172.8M | ||
| Q2 25 | $858.4M | $248.2M | ||
| Q1 25 | $786.2M | $240.8M | ||
| Q4 24 | $1.0B | $195.5M | ||
| Q3 24 | $1.0B | $127.9M | ||
| Q2 24 | $946.8M | $74.2M |
总债务EXASRGLD
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $0 | ||
| Q2 24 | — | $50.0M |
股东权益EXASRGLD
| Q1 26 | — | $7.5B | ||
| Q4 25 | $2.4B | $7.2B | ||
| Q3 25 | $2.5B | $3.4B | ||
| Q2 25 | $2.5B | $3.3B | ||
| Q1 25 | $2.4B | $3.2B | ||
| Q4 24 | $2.4B | $3.1B | ||
| Q3 24 | $3.2B | $3.0B | ||
| Q2 24 | $3.2B | $3.0B |
总资产EXASRGLD
| Q1 26 | — | $9.5B | ||
| Q4 25 | $5.9B | $9.5B | ||
| Q3 25 | $5.9B | $4.5B | ||
| Q2 25 | $5.8B | $3.6B | ||
| Q1 25 | $5.7B | $3.5B | ||
| Q4 24 | $5.9B | $3.4B | ||
| Q3 24 | $6.7B | $3.3B | ||
| Q2 24 | $6.7B | $3.3B |
负债/权益比EXASRGLD
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 0.00× | ||
| Q2 24 | — | 0.02× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $151.7M | $293.6M |
| 自由现金流经营现金流 - 资本支出 | $120.4M | $278.9M |
| 自由现金流率自由现金流/营收 | 13.7% | 59.4% |
| 资本支出强度资本支出/营收 | 3.6% | — |
| 现金转化率经营现金流/净利润 | — | 1.04× |
| 过去12个月自由现金流最近4个季度 | $356.8M | — |
8季度趋势，按日历期对齐
经营现金流EXASRGLD
| Q1 26 | — | $293.6M | ||
| Q4 25 | $151.7M | $241.7M | ||
| Q3 25 | $219.9M | $174.0M | ||
| Q2 25 | $89.0M | $152.8M | ||
| Q1 25 | $30.8M | $136.4M | ||
| Q4 24 | $47.1M | $141.1M | ||
| Q3 24 | $138.7M | $136.7M | ||
| Q2 24 | $107.1M | $113.5M |
自由现金流EXASRGLD
| Q1 26 | — | $278.9M | ||
| Q4 25 | $120.4M | — | ||
| Q3 25 | $190.0M | — | ||
| Q2 25 | $46.7M | — | ||
| Q1 25 | $-365.0K | — | ||
| Q4 24 | $10.7M | — | ||
| Q3 24 | $112.6M | — | ||
| Q2 24 | $71.2M | — |
自由现金流率EXASRGLD
| Q1 26 | — | 59.4% | ||
| Q4 25 | 13.7% | — | ||
| Q3 25 | 22.3% | — | ||
| Q2 25 | 5.8% | — | ||
| Q1 25 | -0.1% | — | ||
| Q4 24 | 1.5% | — | ||
| Q3 24 | 15.9% | — | ||
| Q2 24 | 10.2% | — |
资本支出强度EXASRGLD
| Q1 26 | — | — | ||
| Q4 25 | 3.6% | — | ||
| Q3 25 | 3.5% | — | ||
| Q2 25 | 5.2% | — | ||
| Q1 25 | 4.4% | — | ||
| Q4 24 | 5.1% | — | ||
| Q3 24 | 3.7% | — | ||
| Q2 24 | 5.1% | — |
现金转化率EXASRGLD
| Q1 26 | — | 1.04× | ||
| Q4 25 | — | 2.58× | ||
| Q3 25 | — | 1.37× | ||
| Q2 25 | — | 1.15× | ||
| Q1 25 | — | 1.20× | ||
| Q4 24 | — | 1.31× | ||
| Q3 24 | — | 1.42× | ||
| Q2 24 | — | 1.40× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EXAS
| Screening | $695.1M | 79% |
| Precision Oncology | $183.2M | 21% |
RGLD
| North America | $258.0M | 55% |
| South and Central America | $110.2M | 23% |
| Europe, Middle East, Africa (EMEA) | $84.8M | 18% |
| Australia Pacific | $16.1M | 3% |
